Subsea7 Related Party Transaction
Under the Shareholder Agreement, Eni S.p.A., CDP Equity S.p.A. and Siem Industries S.A. have agreed to vote in favour of the proposed merger. The Shareholders' Agreement further ensures a balanced leadership and governance structure as agreed in the Merger Agreement dated 23 July 2025 between Subsea7 S.A. and Saipem S.p.A. which is in the interests of Subsea7 S.A. and its shareholders.
As the transaction qualifies as a related party transaction under the law of 24 May 2011 on the exercise of certain rights of shareholders in general meetings of listed companies and implementing the so called SRD II EU directive (“SRD II”) Kristian Siem and Louisa Siem did not participate in the vote to approve the above payment in accordance with SRD II and Luxembourg Company Law.
*******************************************************************************
Subsea7 is a global leader in the delivery of offshore projects and services for the evolving energy industry, creating sustainable value by being the industry's partner and employer of choice in delivering the efficient offshore solutions the world needs.
Subsea7 is listed on the Oslo Børs (SUBC), ISIN LU0075646355, LEI 222100AIF0CBCY80AH62.
*******************************************************************************
Contact for investment community enquiries:
Katherine Tonks
Investor Relations Director
Tel +44 20 8210 5568
...
This information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act.
This stock exchange release was published by Katherine Tonks, Investor Relations, Subsea7, on 12 December 2025 at 15:15 CET.
Attachment
-
SUBC related party transaction

Legal Disclaimer:
MENAFN provides the
information “as is” without warranty of any kind. We do not accept
any responsibility or liability for the accuracy, content, images,
videos, licenses, completeness, legality, or reliability of the information
contained in this article. If you have any complaints or copyright
issues related to this article, kindly contact the provider above.

Comments
No comment